Influence of Hyperglycemia on the Prognosis of Patients with Diffuse Large B-Cell Lymphoma

References

• Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(5):604–616. doi:10.1002/ajh.25460
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels, Belgium: International Diabetes Federation; 2021.
   Google Scholar
• Tsilidis KK, Ioannidis JP. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;11(1):350. doi:10.1136/bmj.g7607
   Web of Science ®Google Scholar
• Wang C, Wang X, Gong G, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2012;130(7):1639–1648. doi:10.1002/ijc.26165
   PubMed Web of Science ®Google Scholar
• Li D, Yeung SC, Has San MM, et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009;137(2):482–488. doi:10.1053/j.gastro.2009.04.013
   PubMed Web of Science ®Google Scholar
• Luo J, Beresford S, Chen C, et al. Association between diabetes, diabetes treatment and risk of developing endometrial cancer. Br J Cancer. 2014;111(7):1432–1439. doi:10.1038/bjc.2014.407
   Web of Science ®Google Scholar
• Guraya SY. Association of type 2 diabetes mellitus and the risk of colorectal cancer: ameta-analysis and systematic review. World J Gastroenterol. 2015;21(19):6026–6031. doi:10.3748/wjg.v21.i19.6026
   PubMed Web of Science ®Google Scholar
• Chang YL, Sheu WH, Lin SY, et al. Good glycaemic control is associated with a better prognosis in breast cancer patients with type 2 diabetes mellitus. Clin Exp Med. 2018;18(3):383–390. doi:10.1007/s10238-018-0497-2
   Web of Science ®Google Scholar
• Tseng CH. Diabetes but not insulin increases the risk of lung cancer: a Taiwanese population-based stud. PLoS One. 2014;9(7):e101553. doi:10.1371/journal.pone.0101553
   Web of Science ®Google Scholar
• Gong IY, Cheung MC, Read S, et al. Association between diabetes and haematological malignancies: a population-based study. Diabetologia. 2021;64(3):540–551. doi:10.1007/s00125-020-05338-7
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu X, Yan P, et al. Association between type 1 and type 2 diabetes and risk of non- Hodgkin’s lymphoma: a meta-analysis of cohort studies. Diabetes Metab. 2020;46(1):8–19. doi:10.1016/j.diabet.2019.04.006
   Web of Science ®Google Scholar
• Xu J, Wang T. Association of diabetes mellitus with non-Hodgkin lymphoma risk: a meta- analysis of cohort studies. Hematology. 2019;24(1):527–532. doi:10.1080/16078454.2019.1636485
   PubMed Web of Science ®Google Scholar
• Zhou J, Han S, Qian W, et al. Metformin induces miR-378 to downregulate the CDK1, leading to suppression of cell proliferation in hepatocellular carcinoma. Onco Targets Ther. 2018;11:4451–4459. doi:10.2147/OTT.S167614
   Web of Science ®Google Scholar
• Leng W, Jiang J, Chen B, Wu Q. Metformin and malignant tumors: not over the Hill. Diabetes Metab Syndr Obes. 2021;14:3673–3689. doi:10.2147/DMSO.S326378
   Web of Science ®Google Scholar
• Gandini S, Puntoni M, Heckman-Stoddard BM, et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res. 2014;7(9):867–885. doi:10.1158/1940-6207.CAPR-13-0424
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen R, Deng L, et al. The effect of metformin on the proliferation, apoptosis and CD133 mRNA expression of colon cancer stem cells by upregulation of miR 342-3p. Drug Des Devel Ther. 2021;15:4633–4647. doi:10.2147/DDDT.S336490
   Google Scholar
• Zhang J, Wen L, Zhou Q, et al. Preventative and therapeutic effects of metformin in gastric cancer: a new contribution of an old friend. Cancer Manag Res. 2020;12:8545–8554. doi:10.2147/CMAR.S264032
   Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282. doi:10.1182/blood-2003-05-1545
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068. doi:10.1200/JCO.2013.54.8800
   PubMed Web of Science ®Google Scholar
• International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non- Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987–994. doi:10.1056/NEJM199309303291402
   PubMed Web of Science ®Google Scholar
• Gao R, Liang JH, Man TS, et al. Diabetes mellitus predicts inferior survival in diffuse large B-cell lymphoma: a propensity score-matched analysis. Cancer Manag Res. 2019;11:2849–2870. doi:10.2147/CMAR.S185319
   PubMed Web of Science ®Google Scholar
• Lam C, Cronin K, Ballard R, et al. Differences in cancer survival among white and black cancer patients by presence of diabetes mellitus: estimations based on SEER -Medicare-linked data resource. Cancer Med. 2018;7(7):3434–3444. doi:10.1002/cam4.1554
   PubMed Web of Science ®Google Scholar
• Drozd-Sokolowska J, Zaucha JM, Biecek P, et al. Type 2 diabetes mellitus compromises the survival of diffuse large B- cell lymphoma patients treated with (R) -CHOP - The PLRG report. Sci Rep. 2020;10(1):3517. doi:10.1038/s41598-020-60565-7
   PubMed Web of Science ®Google Scholar
• Yang WS, Li HL, Xu HL, et al. Type 2 diabetes and the risk of non-Hodgkin’s lymphoma: a report from two population-based cohort studies in China. Eur J Cancer Prev. 2016;25(2):149–154. doi:10.1097/CEJ.0000000000000150
   Web of Science ®Google Scholar
• Lamar ZS, Dothard A, Kennedy L, et al. Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non- Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study. Leuk Lymphoma. 2018;59(8):1871–1877. doi:10.1080/10428194.2017.1410889
   PubMed Web of Science ®Google Scholar
• Dehghani M, Hobbi AM, Haghighat S, et al. Glucocorticoid induced diabetes and lipid profiles disorders amongst lymphoid malignancy survivors. Diabetes Metab Syndr. 2020;14(6):1645–1649. doi:10.1016/j.dsx.2020.08.027
   Web of Science ®Google Scholar
• Singh AR, Gu JJ, Zhang Q, et al. Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma. Cancer Meta b. 2020;8(1):10. doi:10.1186/s40170-020-00213-w
   Web of Science ®Google Scholar